Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novavax Amex: NOX. Great news to open monday morning -- Ignore unavailable to you. Want to Upgrade?

To: Jaime Leiderman who wrote (3)	9/28/1998 3:00:00 AM
From: Matt Webster	Read Replies (1) \| Respond to of 38

Just started the due diligence on NOX and it's got decent financials. $11 million book $17.7 million market cap $10 million cash $1 million burn rate 30 million shares outstanding (common) Anyway, I'm not clear whether they wholly own emulsion or whether they share that with DARPA or the Unviersity of Michigan. It's great that we have a weapon against anthrax, but does NOX get to market it or does DARPA or UM have prior rights? Still, seems like a no-brainer to go up. With whopping average volume of 23,000 shares, it'll be an exciting 9:30 AM for the specialist/market maker. There is no report at Zack's, so I don't know about the size of the float, but it's got to be tiny. Perhaps another ENMD? Or another IPIC? Those are the only two drug stocks I ever followed, so it'll probably be like neither! Good luck, Matt